Faculty Opinions recommendation of Effects of transdermal testosterone gel or an aromatase inhibitor on prostate volume in older men.

2017 ◽  
Author(s):  
John Amory
Keyword(s):  
Aromatase Inhibitor ◽  
Prostate Volume ◽  
Older Men ◽  
Testosterone Gel

scholarly journals Effects of transdermal testosterone gel or an aromatase inhibitor on serum concentration and pulsatility of growth hormone in older men with age-related low testosterone

Metabolism ◽  
2017 ◽  
Vol 69 ◽  
pp. 143-147 ◽  
Author(s):  
Jenny Pena Dias ◽  
Johannes D. Veldhuis ◽  
Olga Carlson ◽  
Michelle Shardell ◽  
Chee W. Chia ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Serum Concentration ◽  
Aromatase Inhibitor ◽  
Older Men ◽  
Age Related ◽  
Testosterone Gel ◽  
Low Testosterone

scholarly journals Effects of Transdermal Testosterone Gel or an Aromatase Inhibitor on Prostate Volume in Older Men

2016 ◽  
Vol 101 (4) ◽  
pp. 1865-1871 ◽  
Author(s):  
Jenny Pena Dias ◽  
Denise Melvin ◽  
Michelle Shardell ◽  
Luigi Ferrucci ◽  
Chee W. Chia ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Aromatase Inhibitor ◽  
Prostate Specific Antigen ◽  
Lower Urinary Tract Symptoms ◽  
Lower Urinary Tract ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Older Men ◽  
Urinary Tract Symptoms ◽  
Lower Urinary

Abstract Context: T replacement is being increasingly offered to older men with age-related low T; hence, monitoring prostate health is important during T therapy. Data suggest that estrogens have an independent effect on the prostate and some effects of T on the prostate might be mediated via its aromatization to estradiol. Although some studies have assessed the effects of T replacement on prostate volume, the differential effects of T and estradiol have not been delineated. Objective: The objective of the study was to investigate the relative effects of T and estradiol on prostate volume in older men with low T. Participants: Thirty-one men, 65 years old or older with total T less than 350 ng/dL (measured by mass spectrometry) participated in the study. Intervention: The intervention included randomization to 5 g transdermal T gel (TT), 1 mg oral aromatase inhibitor (AI), or placebo daily for 12 months. Main Outcome Measures: The primary outcome was prostate volume measured by transrectal ultrasound at baseline and 12 months. Secondary outcomes included prostate-specific antigen levels and lower urinary tract symptoms score. Results: Serum T levels increased in both intervention groups; estradiol levels increased in the TT group, whereas it decreased in the AI group. At 12 months, prostate volume significantly increased (4.5 ± 1.76 cc, P < .05) only in the TT group. Increase in prostate-specific antigen levels were seen in both intervention groups at 6 months (P < .01 and P < .001). The lower urinary tract symptoms score increased only in the TT group (P < .05). Conclusion: The tropic effects of T on the prostate are mediated via its aromatization to estradiol. Administration of AI for 12 months to older men was not detrimental to the prostate.

scholarly journals Testosterone vs. aromatase inhibitor in older men with low testosterone: effects on cardiometabolic parameters

Andrology ◽  
2016 ◽  
Vol 5 (1) ◽  
pp. 31-40 ◽  
Author(s):  
J.P. Dias ◽  
M. D. Shardell ◽  
O. D. Carlson ◽  
D. Melvin ◽  
G. Caturegli ◽  
...  
Keyword(s):  
Aromatase Inhibitor ◽  
Older Men ◽  
Low Testosterone

scholarly journals Testosterone Therapy for Men With Age-Related Low Testosterone: Tempest in a Teacup

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. 471-471
Author(s):  
Shehzad Basaria
Keyword(s):  
Cardiovascular Health ◽  
Serum Testosterone ◽  
Older Men ◽  
Normal Range ◽  
Testosterone Levels ◽  
Age Related ◽  
Calcified Plaque ◽  
Testosterone Gel ◽  
Physical Dysfunction ◽  
Low Testosterone

Abstract Serum testosterone concentrations decrease in men with age, but benefits and risks of raising testosterone levels in older men remain controversial. In the T-Trials, a total of 790 men, age 65 and older, with a serum testosterone concentration of < 275 ng/dL and symptoms of sexual dysfunction, fatigue or physical dysfunction were randomized to either testosterone gel or placebo gel for 1 year. Treatment in the testosterone arm increased serum testosterone levels to the mid-normal range for young men. Testosterone replacement was associated with a significant increase in sexual activity (p<0.001), libido and erectile function. In contrast, there was no improvement in vitality or physical function. Adverse findings included increases in non-calcified plaque formation and a higher rate of prostate events. In sum, testosterone treatment in older men was associated with modest benefits, while the risk on prostate and cardiovascular health remain unclear.

scholarly journals Biomarkers and Noncalcified Coronary Artery Plaque Progression in Older Men Treated With Testosterone

2019 ◽  
Vol 105 (7) ◽  
pp. 2142-2149 ◽  
Author(s):  
Kashif Shaikh ◽  
Susan S Ellenberg ◽  
Rine Nakanishi ◽  
Peter J Snyder ◽  
Juhwan Lee ◽  
...  
Keyword(s):  
Older Men ◽  
Plaque Progression ◽  
Primary Analysis ◽  
Anthropometric Measures ◽  
Predictive Variables ◽  
Testosterone Gel ◽  
Low Testosterone ◽  
Testosterone Effect ◽  
Noncalcified Plaque ◽  
Cardiovascular Biomarkers

Abstract Objective Recent results from the Cardiovascular Trial of the Testosterone Trials showed that testosterone treatment of older men with low testosterone was associated with greater progression of noncalcified plaque (NCP). We evaluated the effect of anthropometric measures and cardiovascular biomarkers on plaque progression in individuals in the Testosterone Trial. Methods The Cardiovascular part of the trial included 170 men aged 65 years or older with low testosterone. Participants received testosterone gel or placebo gel for 12 months. The primary outcome was change in NCP volume from baseline to 12 months, as determined by coronary computed tomography angiography (CCTA). We assayed several markers of cardiovascular risk and analyzed each marker individually in a model as predictive variables and change in NCP as the dependent variable. Results Of 170 enrollees, 138 (73 testosterone, 65 placebo) completed the study and were available for the primary analysis. Of 10 markers evaluated, none showed a significant association with the change in NCP volume, but a significant interaction between treatment assignment and waist-hip ratio (WHR) (P = 0.0014) indicated that this variable impacted the testosterone effect on NCP volume. The statistical model indicated that for every 0.1 change in the WHR, the testosterone-induced 12-month change in NCP volume increased by 26.96 mm3 (95% confidence interval, 7.72-46.20). Conclusion Among older men with low testosterone treated for 1 year, greater WHR was associated with greater NCP progression, as measured by CCTA. Other biomarkers and anthropometric measures did not show statistically significant association with plaque progression.

scholarly journals Correlation between body mass index and prostate volume in benign prostatic hyperplasia patients undergoing holmium enucleation of the prostate surgery

BMC Urology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Ken Batai ◽  
Michael Phung ◽  
Robert Bell ◽  
Aye Lwin ◽  
Kieran A. Hynes ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Regression Analysis ◽  
Hispanic Americans ◽  
Prostate Volume ◽  
Linear Regression Analysis ◽  
Positive Association ◽  
Older Men ◽  
Prostatic Hyperplasia ◽  
European Americans ◽  
Age At Surgery

Abstract Background Benign prostatic obstruction (BPO) due to benign prostatic hyperplasia (BPH) is a leading cause of morbidity in men over the age of 40. This study examined whether there was an association between body mass index (BMI) and pre-operative prostate volume and whether expression of two genes, alpha-2-macroglobulin (A2M) and transforming growth factor beta 3 (TGFB3), was correlated with BMI, pre-operative prostate volume, and age at surgery. Methods Medical records of patients who underwent holmium enucleation of the prostate surgery for treatment of BPO were retrospectively reviewed. Surgical specimens were obtained from formalin-fixed paraffin-embedded blocks, and expression of the targeted genes was quantified using a real time PCR approach. Linear regression analysis was performed to assess association between BMI and prostate volume adjusting for demographic characteristics and co-morbidity. Spearman’s correlation was used to examine whether gene expression was correlated with BMI, prostate volume, and age at surgery. Results A total of 278 patients were identified, including 62.9% European Americans (n = 175) and 27.7% Hispanic Americans (n = 77). BMI was significantly correlated with prostate volume (Spearman’s rho = 0.123, P = 0.045). In linear regression analysis, BMI was positively associated with prostate volume (β = 0.01, P = 0.004), while hyperlipidemia was negatively associated with prostate volume (β = −0.08, P = 0.02). A trend for a positive association was also observed for diabetes (β = 0.07, P = 0.099). In the race/ethnicity stratified analysis, age at surgery showed a trend for significantly positive association with prostate volume in European Americans (β = 0.005, P = 0.08), but not in Hispanic Americans. Expression of the A2M gene in the stroma was negatively correlated with age at surgery (P = 0.006). A2M expression in the gland was positively correlated with prostate volume among older men (Age ≥ 70, P = 0.01) and overweight men (BMI 25–30, P = 0.04). TGFB3 expression in the gland was positively correlated with BMI (P = 0.007) among older men. Conclusions This study demonstrated the positive correlation between BMI and prostate volume. Expression of TGFB3 and A2M was correlated with BMI, prostate volume, and age at surgery.

Sign in / Sign up

Export Citation Format

Share Document